Sun.Dec 04, 2022

article thumbnail

Humira biosimilars set the stage for long-awaited 2023 US launches

Pharmaceutical Technology

Starting in January, multiple biosimilars of AbbVie’s blockbuster drug Humira are set to flood the US pharmaceutical market. The arrival of Humira biosimilars is expected to provide cost-effective alternatives to the anti-tumor necrosis factor (TNF) biologic, but their eventual position on the market remains to be seen. Moreover, Humira’s behemoth status makes their introduction in the US particularly interesting.

Pharmacy 262
article thumbnail

In the hunt for a male contraceptive, scientists look to stop sperm in their tracks

NPR Health - Shots

For decades birth control research focused on women. Now there's a new push to develop gels, pills or other products that could keep men from getting their partners pregnant.

Scientist 141
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Elon Musk’s Neuralink brain interface chip set for human trials

pharmaphorum

Clinical trials of a wireless brain chip developed by Elon Muck’s Neuralink company will be tested in human volunteers within the next six months – and Musk himself says he intends to have one implanted for a future demo event. Neuralink has been promising that the technology will be ready for clinical trials soon for some time – first saying they were around the corner back in 2019 – so the latest announcement by Musk at an update last week may be met with some scepticism.

Trials 118
article thumbnail

When COVID closed India, these women opened their hearts — and wallets

NPR Health - Shots

Sangeeta Siwan lost her job and wasn't able to pay rent or feed her family. Her neighbors helped her survive. A study of giving in India during the pandemic shows she wasn't alone.

132
132
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Addressing leadership barriers for women in tech and pharma

pharmaphorum

Contrary to Big Tech, historically the pharmaceutical industry has had a good reputation for being a female-positive industry. However, both industries share a common problem: failure to provide women with C-suite opportunities. In fact, women hold only 11% of executive positions at Silicon Valley companies. The biopharma industry is worse, with women only accounting for 8% of CEO roles.

article thumbnail

Protracted Job Searches Exact Weighty Mental Health Toll

BioSpace

Whether a job search is voluntary or not, the psychological toll of months of interviews, wrangling over pay and benefits and evaluating options has a weighty psychological toll.

100
100

More Trending

article thumbnail

SonoThera Bags $60M for Ultrasound-Guided, Non-Viral Gene Therapy

BioSpace

???????SonoThera closed its Series A round of financing Monday, counting $60.75 million in earnings and will use these proceeds to advance its ultrasound-guided, non-viral gene therapy platform.

article thumbnail

Amgen to push latecomer obesity drug into midstage testing

pharmaphorum

Amgen is lagging behind rivals like Novo Nordisk and Eli Lilly with its new-generation therapy for obesity, but is sufficiently encouraged by early-stage clinical data to kick off a phase 2 programme for the drug next year. AMG 133 is a bispecific molecule that addresses two targets, GLP-1 and GIPR, and in a phase 1 study achieved clinically significant body weight reductions over 12 weeks in people with obesity and without diabetes, according to Amgen.

Drugs 101
article thumbnail

FUJIFILM Diosynth Biotechnologies: There’s a New Cell Therapy Employer in Thousand Oaks

BioSpace

FUJIFILM Diosynth Biotechnologies is offering unique opportunities to join one of the top global CDMOs focused on solving some of the most complex healthcare challenges.

98
article thumbnail

China reports 2 new COVID deaths as some restrictions eased

Medical Xpress

China on Sunday reported two additional deaths from COVID-19 as some cities move cautiously to ease anti-pandemic restrictions amid increasingly vocal public frustration over the measures.

90
article thumbnail

Running Decentralized Trials at Scale: Planning for Success

There’s been a rapid shift towards decentralization in clinical trials & it’s clear why. The potential for reaching a larger pool of recruits is possible when sponsors can bring more trial activities to the patient. Tele visits, digital consent, new monitoring sensors, & direct-to-patient supply are virtual tools that existed before the pandemic, but now there’s swift adoption of these methods because they’ve been proven to help launch & complete trials more effectively.

article thumbnail

FDA Outlines Path Forward for Verve’s Lead Candidate, VERVE-101

BioSpace

Monday, Verve Therapeutics revealed that the FDA has officially requested several buckets of additional safety information to lift the hold on its lead candidate, VERVE-101.

97
article thumbnail

Understanding 'immunity debt', or why so many kids seem to be falling sick at once

NPR Health - Shots

Many kids are getting sick at the same time. NPR's Ayesha Rascoe asks Vox senior public health reporter Dr. Keren Landman about the concept of "immunity debt.

95
article thumbnail

Janssen Bows Out as Contender for Horizon Therapeutics Buyout

BioSpace

Janssen (Johnson & Johnson) is no longer in the running to acquire rare disease player Horizon Therapeutics, the company announced Saturday. This leaves Amgen and Sanofi at the bidding table.

96
article thumbnail

Sex, Racial, and Ethnic Representation in COVID-19 Clinical Trials

JAMA Internal Medicine

This systematic review and meta-analysis investigates whether female participants and racial and ethnic minority individuals are adequately represented in COVID-19 prevention and treatment trials in the US.

article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

In Face of Multiple Patent Cliffs, Novartis' Prostate Cancer Drug Shows Promise

BioSpace

Novartis announced the Phase III PSMAfore trial of Pluvicto for PSMA-positive metastatic castration-resistant prostate cancer met its primary endpoint.

Drugs 77
article thumbnail

New patent expiration for Allergan drug VIIBRYD

Drug Patent Watch

Annual Drug Patent Expirations for VIIBRYD Viibryd is a drug marketed by Allergan and is included in one NDA. It is available from four suppliers. There are four patents protecting…. The post New patent expiration for Allergan drug VIIBRYD appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

Novo Nordisk & ATLATL announce winners in their joint program EntreStar Novo Nordisk Research Centre China and ATLATL jointly announce the winners of EntreStar program. Innovent and UNION Therapeutics Announce First Subject Dosed in a Chinese Clinical Phase I Study of the Novel PDE4 Inhibitor Orismilast (IBI353) Innovent Biologics, Inc. and UNION therapeutics A/S announced that the first Chinese healthy volunteer has been successfully dosed in the Phase I study of orismilast, a potential best-in-class PDE4 inhibitor in global clinical Phase II stage. Seoul National University Bundang Hospital Presents Study of SK Biopharmaceuticals' Seizure Detection Wearable Device at AES 2022 Seoul National University Bundang Hospital presented its preliminary study result of seizure monitoring for patients with epilepsy using SK Biopharmaceuticals' multimodal wearable device at the American Epilepsy Society Annual Meeting 2022 in Nashville, Tennessee, December 2-6. Pictor announces funding round after successful launch in

BioSpace

TauRx Pharmaceuticals and Anavex Life Sciences presented positive results from their candidates at the Clinical Trials in Alzheimer’s Disease (CTAD) conference in San Francisco, CA.

article thumbnail

New tentative approval for Amneal Pharms drug saxagliptin

Drug Patent Watch

[![saxagliptin structure]([link] Saxagliptin is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are two patents protecting this compound. There are…. The post New tentative approval for Amneal Pharms drug saxagliptin appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

A new policy in New York City makes it easier for homeless people to be forcibly hospitalized

NPR Health - Shots

In New York City, Mayor Eric Adams plans to move homeless people with seeming mental illness to hospitals, possibly involuntarily.

66
article thumbnail

New tentative approval for Teva Pharms drug eltrombopag

Drug Patent Watch

[![eltrombopag structure]([link] Eltrombopag is the generic ingredient in two branded drugs marketed by Novartis and is included in two NDAs. There are eight patents protecting this compound. There are four…. The post New tentative approval for Teva Pharms drug eltrombopag appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

Which pharmaceutical drugs have the most drug patents in Eurasian Patent Organization?

Drug Patent Watch

This chart shows the drugs with the most patents in Eurasian Patent Organization. Patents must be filed in each country (or, in some cases regional patent office) where patent protection…. The post Which pharmaceutical drugs have the most drug patents in Eurasian Patent Organization? appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 40